Overview:
Regenerative medicine, is upcoming interdisciplinary field which makes use of both engineering and life science knowledge, to regenerate, restore diseased and injured tissues and whole organ. This would aid to overcome the hurdles caused during the transplantation of intact organ and tissues to treat organ and tissue failure and loss caused due to limited donor supply and often severe immune complication. Regenerative medicine is evolving field able to recreate or harness the body’s innate healing capacity as well as normalise the congenital defects.
Regenerative medicine depicts new paradigm shift in healthcare sector with potential to address unmet needs by focusing on the underlying causes of disease. The surge in prevalence of degenerative diseases is one key driver for growth. The most economical diseases which are chronic and disproportionately affect elderly such as diabetes, neurodegenerative disorder, stroke, cardiovascular disease etc, regenerative medicine would help to alter the course treatment and lower the healthcare cost. With development of stem cell therapies, which is being applied in various medical condition to restore body function and improving quality of patient’s life is driving force for regenerative medicine market. Looking at this transformative future in the field of medicine, many research centers, disease foundation, pharmaceutical and biotechnology companies have made investment in regenerative medicine. The regenerative medicine has edge over the existing treatment, in terms of economic benefits, as they are curative in nature rather than palliative or aiming at delaying the progression of disease, rather than addressing the underlying cause. Though challenges exist in terms of stringent legislation and delay in the regulatory affairs, which need to address for the smooth entry of regenerative product in the market
According to report of Tufts University School of Medicine, the regenerative medicine sector in Europe, Japan and the U.S. includes more than 640 privately held and publicly traded companies. In US, recently number of merger and acquisition by leading vendors taking place, thus attracting public as well private funding in regenerative medicine field. For instance, in November 2012, Smith & Nephew acquired Healthpoint Biotherapeutics for US$782 million. These acquisitions have resulted in a better vendor product portfolio and have a positive impact on the growth of the market. The Japan and Asia-pacific region is the fastest growing market for the regenerative medicine therapies through 2020. The major driver in Japan being new legislation and relaxation of regulation which would help with safer and faster provision of the innovative products. The key drivers for Asia Pacific Market include increase awareness, advancement in nanotechnology, technological innovations in stem cell therapy and tissue engineering, growing prevalence of bone and joint diseases , need for orthopedic surgeries.
The global Regenerative Medicine Market is segmented on the following bases:
Key Players Identified for Regenerative Medicine Market Include but are Not Limited to:
Baxter International Inc., Johnson and Johnson Ltd. , Kinetic Concepts Inc., Medtronic Inc., Stryker Corp., ZimmerBiomet, Acelity, MiMedx Group, UniQure, DePuy Synthes, Arthrex, Inc. Smith & Nephew plc, Japan Tissue Engineering Co., Ltd, Celgene Corporation, StemCells, Inc., Vericel Corporation
This report offers:
